Shares of a company engaged in the manufacture and sales of pharma intermediated and bulk drugs are in focus during the trading session of Tuesday, after reporting Q3 FY25 financial results with a rise in net pr of around 25 percent QoQ and 421 percent YoY.
With a market cap of Rs. 79.24 crores, the shares of Astal Laboratories Limited opened in the green at Rs. 86.9, up by around 2.4 percent, as compared to its previous closing price of Rs. 84.85.
What’s the news
The fluctuations in the share prices were observed after Astal Laboratori Limited announced the financial results for Q3 FY25, through the rece filings with the BSE.
For Q3 FY25, Astal Laboratories reported revenue from operations of Rs. 14.5 crores, registering an increase of around 10 percent QoQ from Rs. 13.2 crores in Q2 FY25, as well as a rise of about 72.6 percent YoY from Rs. 8.4 crores in Q3 FY24.
The company’s net profit for Q3 FY25 grew to Rs. 2.5 crores, represent a significant rise of around 25 percent QoQ from Rs. 2 crores in Q2 FY2 and a year-on-year increase of nearly 421 percent from Rs. 0.48 crores in Q3 FY24.
Stock Performance
The stock has delivered multibagger returns of nearly 117 percent of returns in one year, while around 8 percent of positive returns in the last six months. Meanwhile, the shares of Astal Laboratories have declined by around 0.5 percent in the last one month.
About the Company
Astal Laboratories Limited, previously known as Macro International Limited, is presently engaged in the business of manufacturing and sales of pharmaceutical intermediates and bulk drugs.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
